Australia's most trusted
source of pharma news
Saturday, 02 August 2025
Posted 1 August 2025 PM
Two drugs have been subsidised on the PBS for the first time from 1 August, while some big names saw expansions to their indications and others faced the entry of the first biosimilar competition.
AbbVie's Vyalev has been listed for the treatment of advanced idiopathic Parkinson's in people with severe motor fluctuations despite optimised alternative pharmacological treatment.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.